May 2024 Tender Notification
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022 and in the 2023/24 Invitation to Tender dated 31 October 2023.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on the 12th of June 2024 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website
Process for notification of product changes (NOPC)
Suppliers are required to ensure that a Pharmacode(external link) has been obtained from the Pharmacy Guild of New Zealand and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the fifth of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
- 31 May 2024 Tender notification [PDF 181 KB]
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Metronidazole |
Tab 200 mg; 250 tablet bottle pack |
$33.15 |
$25.86 |
Metromed (Medsurge) |
1 October 2024 |
1 March 2025 |
Metrogyl (Viatris) |
|
Metronidazole |
Tab 400 mg; 21 tablet blister pack |
$5.23 |
$4.29 |
Metromed (Medsurge) |
1 October 2024 |
1 March 2025 |
Metrogyl (Viatris) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Metronidazole |
Tab 200 mg; 250 tablet bottle pack |
$33.15 |
$25.86 |
Metromed (Medsurge) |
5% |
1 October 2024 |
1 March 2025 |
Metrogyl (Viatris) |
|
Metronidazole |
Tab 400 mg; 21 tablet blister pack |
$5.23 |
$4.29 |
Metromed (Medsurge) |
5% |
1 October 2024 |
1 March 2025 |
Metrogyl (Viatris) |
2023/24 Tender – Principal Supply Status applies until 30 June 2027
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
3. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Aqueous cream |
Crm; 500 g tub |
$1.73 |
$1.65 |
Evara (Evara) |
1 October 2024 |
1 March 2025 |
GEM Aqueous Cream (BioInnova) healthE Aqueous Cream SLS Free (Jaychem) |
|
Baclofen |
Inj 2 mg per ml, 5 ml ampoule; 10 ampoule pack |
$306.82 (5 pack) |
$490.91 |
Baclofen Sintetica (Boucher) |
1 October 2024 |
1 March 2025 |
Medsurge (Medsurge) |
|
Clonidine hydrochloride |
Inj 150 mcg per ml, 1 ml ampoule; 5 ampoule pack |
$29.68 |
$14.10 |
Catapres (Clinect) |
1 August 2024 |
1 January 2025 |
Clonidine HCL-Medsurge (Medsurge) |
|
Entacapone |
Tab 200 mg; 100 tablet bottle pack |
$18.04 |
$13.73 |
Entapone (Viatris) |
1 February 2025 |
1 July 2025 |
Comtan (Max Health) |
|
Modafinil1 |
Tab 100 mg; 30 tablet blister pack |
$29.13 (60 pack) |
$14.27 |
Modafinil (Max Health) |
1 December 2024 |
1 May 2025 |
Modavigil (Teva) |
|
1Brand Switch Fee of $4.50 is payable for this product from 1 May 2025 until 1 September 2025. |
|||||||
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
4. Tenders awarded pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Aqueous Cream |
Crm; 100 g tube |
$1.25 |
Evara (Evara) |
5% |
1 October 2024 |
1 March 2025 |
5. Tenders awarded pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Aqueous Cream |
Crm; 500 g tub |
$1.73 |
$1.65 |
Evara (Evara) |
5% |
1 October 2024 |
1 March 2025 |
GEM Aqueous Cream (BioInnova) |
|
Baclofen |
Inj 2 mg per ml, 5 ml ampoule; 10 ampoule pack |
$306.82 (5 pack) |
$490.91 |
Baclofen Sintetica (Boucher) |
5% |
1 October 2024 |
1 March 2025 |
Medsurge (Medsurge) |
|
Clonidine hydrochloride |
Inj 150 mcg per ml, 1 ml ampoule; 5 ampoule pack |
$29.68 |
$14.10 |
Catapres (Clinect) |
5% |
1 August 2024 |
1 January 2025 |
Clonidine HCL-Medsurge (Medsurge) |
|
Entacapone |
Tab 200 mg; 100 tablet bottle pack |
$18.04 |
$13.73 |
Entapone (Viatris) |
5% |
1 February 2025 |
1 July 2025 |
Comtan (Max Health) |
|
Flumazenil |
Inj 0.1 mg per ml, 5 ml ampoule; 5 ampoule pack size |
$110.12 (10 pack) |
$44.00 |
Flumazenil-Baxter (Baxter) |
5% |
1 July 2024 |
1 December 2024 |
Hameln (Max Health) |
|
Modafinil |
Tab 100 mg; 30 tablet blister pack |
$29.13 (60 pack) |
$14.27 |
Modafinil (Max Health) |
5% |
1 December 2024 |
1 May 2025 |
Modavigil (Teva) |
|
Terlipressin |
Inj 0.2 mg per ml, 5 ml vial; 5 vial pack |
$215.00 |
$110.00 |
Terlipressin Ever Pharma (InterPharma) |
5% |
1 September 2024 |
1 February 2025 |
Glypressin (Pharmaco) |
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.
|
Chemical Name |
Line Item |
|---|---|
|
Benzylpenicillin sodium |
Inj 1.2 g |
|
Benzylpenicillin sodium |
Inj 3 g |
|
Epirubicin |
Inj 2 mg per ml, 100 ml |
|
Epirubicin |
Inj 2 mg per ml, 25 ml |
|
Epirubicin |
Inj 2 mg per ml, 5 ml |
|
Glyceryl Trinitrate |
Oint 0.2% |
|
Sodium citrate |
Oral liq 8.8 % (300 mmol/l) |
For products included in the 2022/23 and 2023/24 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.